Michael S. Turner Sells 9,672 Shares of 908 Devices Inc. (NASDAQ:MASS) Stock

908 Devices Inc. (NASDAQ:MASS - Get Free Report) insider Michael S. Turner sold 9,672 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $2.33, for a total value of $22,535.76. Following the sale, the insider now owns 24,603 shares of the company's stock, valued at $57,324.99. This trade represents a 28.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

908 Devices Price Performance

MASS stock traded down $0.19 on Friday, hitting $2.36. 255,683 shares of the company were exchanged, compared to its average volume of 1,146,142. The stock has a market capitalization of $82.18 million, a price-to-earnings ratio of -1.33 and a beta of 0.99. 908 Devices Inc. has a twelve month low of $1.81 and a twelve month high of $7.91. The business's fifty day moving average is $2.34 and its two-hundred day moving average is $3.22.

Institutional Trading of 908 Devices

Institutional investors and hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in 908 Devices by 88.3% during the second quarter. Dimensional Fund Advisors LP now owns 245,176 shares of the company's stock worth $1,263,000 after acquiring an additional 114,987 shares during the last quarter. Renaissance Technologies LLC increased its position in 908 Devices by 79.4% during the 2nd quarter. Renaissance Technologies LLC now owns 195,500 shares of the company's stock worth $1,007,000 after purchasing an additional 86,500 shares in the last quarter. Marshall Wace LLP purchased a new position in 908 Devices in the second quarter valued at approximately $229,000. Squarepoint Ops LLC acquired a new position in 908 Devices during the second quarter valued at approximately $250,000. Finally, AQR Capital Management LLC purchased a new stake in 908 Devices during the second quarter worth approximately $585,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

MASS has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (e+)" rating on shares of 908 Devices in a research report on Saturday, February 1st. Stephens restated an "overweight" rating and set a $6.00 target price on shares of 908 Devices in a research report on Wednesday, January 15th. Stifel Nicolaus dropped their price target on 908 Devices from $17.00 to $6.00 and set a "buy" rating for the company in a research report on Wednesday, November 13th. Leerink Partnrs downgraded 908 Devices from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, November 13th. Finally, Leerink Partners restated a "market perform" rating and issued a $4.00 target price (down from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, 908 Devices currently has a consensus rating of "Moderate Buy" and an average target price of $5.33.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.